@article{89e6609078ce4de9af8e6df193fe3507,
title = "An expanded universe of cancer targets",
abstract = "The characterization of cancer genomes has provided insight into somatically altered genes across tumors, transformed our understanding of cancer biology, and enabled tailoring of therapeutic strategies. However, the function of most cancer alleles remains mysterious, and many cancer features transcend their genomes. Consequently, tumor genomic characterization does not influence therapy for most patients. Approaches to understand the function and circuitry of cancer genes provide complementary approaches to elucidate both oncogene and non-oncogene dependencies. Emerging work indicates that the diversity of therapeutic targets engendered by non-oncogene dependencies is much larger than the list of recurrently mutated genes. Here we describe a framework for this expanded list of cancer targets, providing novel opportunities for clinical translation. Members of the Cancer Target Discovery and Development Network synthesize recent insights into the different classes and characteristics of cancer therapeutic vulnerabilities.",
author = "{the Cancer Target Discovery and Development Network} and Hahn, {William C.} and Bader, {Joel S.} and Braun, {Theodore P.} and Andrea Califano and Clemons, {Paul A.} and Druker, {Brian J.} and Ewald, {Andrew J.} and Haian Fu and Subhashini Jagu and Kemp, {Christopher J.} and William Kim and Kuo, {Calvin J.} and Michael McManus and {B. Mills}, Gordon and Xiulei Mo and Nidhi Sahni and Schreiber, {Stuart L.} and Talamas, {Jessica A.} and Pablo Tamayo and Tyner, {Jeffrey W.} and Wagner, {Bridget K.} and Weiss, {William A.} and Gerhard, {Daniela S.} and Vlado Dancik and Shubhroz Gill and Bruce Hua and Tanaz Sharifnia and Vasanthi Viswanathan and Yilong Zou and {Dela Cruz}, Filemon and Andrew Kung and Brent Stockwell and Jesse Boehm and Josh Dempster and Robert Manguso and Francisca Vazquez and Cooper, {Lee A.D.} and Yuhong Du and Andrey Ivanov and Sagar Lonial and Moreno, {Carlos S.} and Qiankun Niu and Taofeek Owonikoko and Suresh Ramalingam and Matthew Reyna and Wei Zhou and Carla Grandori and Ken Chen and Han Liang and Lo, {Yuan Hung}",
note = "Funding Information: Data generated by the CTD 2 Network can be found in the Data Portal and Dashboard. More information about the centers can be found on the Network web site. CTD 2 Centers are funded in part by NCI grants U01 CA217846, U01 CA217858, U01 CA217862, U01 CA217875, U01 CA176058, U01 CA217883, U01 CA217851, U01 CA217882, U01 CA217842, U01 CA217848, U01 CA21788, and U01 CA217864. Funding Information: W.K. and P.T. receive research support from Pfizer Oncology. Funding Information: B.J.D. is an SAB member of Aileron Therapeutics, Therapy Architects (ALLCRON), Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, Novartis, Gilead Sciences (inactive), Monojul (inactive); is an SAB member and holds stock in Aptose Biosciences, Blueprint Medicines, EnLiven Therapeutics, Iterion Therapeutics, Third Coast Therapeutics, GRAIL (SAB inactive); is a scientific founder of MolecularMD (inactive, acquired by ICON); is a member of the board of directors holds stock in Amgen; is a member of the board of directors of Burroughs Wellcome Fund and CureOne; is a member of the Joint Steering Committee of Beat AML LLS; is a founder of VB Therapeutics; has a sponsored research agreement for EnLiven Therapeutics; has clinical trial funding from Novartis, Bristol-Myers Squibb, Pfizer; and collects royalties from patent 6958335 (Novartis) and OHSU and Merck and one CytoImage exclusive license. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2021",
month = mar,
day = "4",
doi = "10.1016/j.cell.2021.02.020",
language = "English (US)",
volume = "184",
pages = "1142--1155",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "5",
}